FORWARD PHARMA A/S Notice of Delisting
On December 16, 2022, Forward Pharma A/S (the "Company") received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that Nasdaq believes that the Company is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. The Company will not appeal this determination. Therefore, the Company expects the trading of its American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. Additionally, the Company intends to file with the SEC a Form 15 requesting the suspension of the Company's reporting obligations.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Forward Pharma A/S published this content on 19 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 December 2022 11:44:13 UTC.
